Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Status:
Recruiting
Trial end date:
2021-06-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating
patients with germline BRCA mutated breast cancer that has spread to other places in the body
(advanced or metastatic). Olaparib, cediranib, and AZD6738 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.